EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 135 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is 1.57 and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $2,018,000 | -28.7% | 47,508 | -19.4% | 0.42% | -25.1% |
Q2 2020 | $2,830,000 | -30.3% | 58,977 | -33.2% | 0.56% | -10.3% |
Q1 2020 | $4,061,000 | -60.2% | 88,273 | -48.1% | 0.63% | -35.5% |
Q4 2019 | $10,214,000 | -26.2% | 170,008 | -30.5% | 0.98% | -6.8% |
Q3 2019 | $13,842,000 | +22.7% | 244,695 | +20.7% | 1.05% | +29.7% |
Q2 2019 | $11,284,000 | +73.3% | 202,652 | +57.2% | 0.81% | +70.3% |
Q1 2019 | $6,510,000 | -99.9% | 128,945 | -4.9% | 0.47% | +7.5% |
Q4 2018 | $5,461,471,000 | -32.9% | 135,554 | +15.5% | 0.44% | -16.0% |
Q3 2018 | $8,136,846,000 | +435.5% | 117,364 | +484.4% | 0.52% | +377.3% |
Q2 2018 | $1,519,480,000 | +629.2% | 20,083 | +407.8% | 0.11% | +587.5% |
Q1 2018 | $208,389,000 | -97.4% | 3,955 | -96.2% | 0.02% | -97.9% |
Q2 2017 | $8,160,697,000 | +2757.3% | 103,444 | +3111.5% | 0.76% | +1655.8% |
Q4 2015 | $285,606,000 | – | 3,221 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |